Subscribe to press release roundup

To regularly receive important releases about Endeavour Vision and portfolio companies

Title *
First name *
Last name *
E-mail *
July 31, 2013
Merz Pharma takes over Swiss dermatology specialist Neocutis

July 8, 2013
OncoEthix Closes 18 Million CHF (~US$19 Million) Series B Financing

June 22, 2013
New Data Demonstrate Simple Insulin Delivery Device Can Significantly Reduce Barriers to Insulin Treatment Among People with Type 2 Diabetes

April 22, 2013
BIND Therapeutics and AstraZeneca Announce Worldwide Development and Commercialization Agreement for Cancer Nanomedicine

April 3, 2013
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins

February 28, 2013
CeQur Announces Positive Results from Study Evaluating Simple Insulin Delivery Device Among People with Type 2 Diabetes

January 17, 2013
Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its

January 8, 2013
BIND Biosciences and Amgen Sign Agreement For The Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine

November 27, 2012
CeQur Receives CE Mark for PaQ® Insulin Delivery Device

November 12, 2012
Molecular Partners enters into a strategic collaboration agreement with Boehringer Ingelheim to support its proprietary pipeline with clinical supply of DARPin® molecules

October 22, 2012
Symetis ACURATE TF™ FIM Trial Completed

September 26, 2012
CeQur Completes Study Evaluating Ability of Simple Insulin Delivery Device to Replace Insulin Injections Among People with Type 2 Diabetes

September 20, 2012
BIND Is Granted Five U.S. Patents Covering BIND-014 and Accurin(TM) Platform

August 21, 2012
Allergan and Molecular Partners Enter into Exclusive Alliance

July 25, 2012
Nfocus Neuromedical, Inc. Announces Positive One-Year Follow-Up Results from Clinical Study of Luna(TM) Aneurysm Embolization System

July 16, 2012
BIND Biosciences appoints Andrew J. Hirsch as Chief Financial Officer

June 22, 2012
BIND Biosciences CEO Scott Minick and Founder Omid Farokhzad Win Ernst & Young New England Entrepreneur of the Year Award

June 16, 2012
Clinical Study begins on Insulin Delivery Device for Type 2s

June 15, 2012
OncoEthix In-Licenses OTX015, an anticancer Bromodomain inhibitor from Mitsubishi Tanabe Pharma Corporation

May 31, 2012
Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as Chief Medical Officer

May 15, 2012
PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System

April 4, 2012
BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers

January 27, 2012
Daniel Bertholet of Endeavour Vision speaks at SECA event

December 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

October 27, 2011
BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline

September 30, 2011
Symetis’ ACURATE TA™ Aortic Bioprosthesis Receives CE Mark Certification on Sept. 30th 2011

May 18, 2011
Symetis reports on its trans-apical ACURATE TA™ clinical

May 4, 2011
Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

April 28, 2011
Molecular Partners reports positive results from its first clinical studies

April 6, 2011
BIND Biosciences Receives 2011 Edison Award

February 15, 2011
Nfocus Neuromedical, Inc. Luna™ Aneurysm Embolization System Receives CE Mark

February 11, 2011
BIND Biosciences featured in the London Times

February 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

January 7, 2011
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014

January 4, 2011
PneumRx, Inc. Raises $33 Million in Capital

November 15, 2010
Endotis Pharma reports successful completion of the neutralization study of the anticoagulant EP217609 by avidin in healthy subjects

October 7, 2010
Symetis closes CHF 25 million financing led by Endeavour Vision and NBGI Ventures, Eric Milledge appointed Chairman of the Board

September 1, 2010
Molecular Partners selected as Technology Pioneer 2011 by the World Economic Forum

June 29, 2010
BIND Biosciences Secures $12.4 Million Financing

June 2, 2010
Kuros completes patient recruitment in Phase IIb study of KUR-113 in patients with tibial shaft fractures

March 15, 2010
Kuros meets primary efficacy endpoint in Phase IIb study with KUR-111

December 15, 2009
Molecular Partners Secures CHF 46 Million in a Series B Financing

October 7, 2009
CeQur SA Appoints Eric Milledge Chairman of the Board of Directors

August 27, 2009
Lumavita AG announces Marketing Authorisation for Pentamycin in Switzerland

August 12, 2009
Kuros announces encouraging Phase IIa data with KUR-212 in patients with burns requiring mesh grafting

July 13, 2009
NovImmune successfully completes NI-0801 Phase I clinical study

July 7, 2009
Kuros starts Phase IIb clinical trial with DUR-211 for diabetic foot ulcers

June 18, 2009
Lumavita AG announces new funding

June 8, 2009
Kuros Completes patient recruitment in a phase IIb trial of KUR-111 in patients with tibal plateau fractures

May 19, 2009
Endotis Pharma reports successful completion of phase I program with EP42675, a first in class synthetic parenteral anticoagulant

May 12, 2009
NovImmune completes CHF 62.5 (USD 54.8) million equity financing to move portfolio forward and reacquire product rights to lead antibodies

March 24, 2009
Lumavita AG announces receipt of Preliminary Approval for Marketing Authorisation of pentamycin in Switzerland for the treatment of

February 27, 2009
Novalar Announces the Launch of OraVerse™ the First Dental Anesthesia Reversal Agent

January 5, 2009
CeQur SA Completes Series A Investment with 10 Million Dollar Raise in December 2009

September 23, 2008
Kuros and Aeris Announce Exclusive License Agreement in the Field of Lung Volume Reduction

September 8, 2008
Pall Corporation Acquires Molecular Diagnostics Manufacturer GeneSystems

January 23, 2008
Endotis Pharma Raises €25 million in a Second Financing Round

January 15, 2008
Molecular Partners AG collaborates with Centocor Research & Development, Inc.

August 14, 2007
Molecular Partners Raises 18.5 Mio CHF in Series A Financing

February 22, 2007
Allergan announces its acquisition of Endoart

February 22, 2007
Kuros receives orphan drug designation for a novel fusion protein for the treatment of solitary bone cysts

October 30, 2006
NovImmune raises CHF 58 million in Series B Private Financing

Frankfurt, July 31, 2013 – Merz Pharma Group (Frankfurt am Main) today announced that it has acquired the Swiss pharmaceutical company Neocutis S.A. The acquisition of the company`s cosmeceutical skin care business strengthens Merz`s market position in the field of aesthetic dermatology.

"Neocutis is an innovative company with an excellent presence on the U.S. market, and a promising potential for development," said Philip Burchard, CEO of Merz Pharma. "This transaction is an important step to expand our U.S. business, as Neocutis products are an excellent addition to our own aesthetics portfolio." The products are particularly used as pre- and post-treatments to aesthetic procedures.

The acquisition of Neocutis reflects the company's strategy to establish itself as a leader in the field of medical and aesthetic dermatology. The U.S. is the most important market for Merz. Merz North America is an important player in aesthetics and medical dermatology, of ...

© Endeavour Vision SA 2006-2017 Terms & Conditions